<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664738</url>
  </required_header>
  <id_info>
    <org_study_id>18-004995</org_study_id>
    <nct_id>NCT04664738</nct_id>
  </id_info>
  <brief_title>PEP on a Skin Graft Donor Site Wound</brief_title>
  <official_title>A Phase I Open-Label Trial to Determine the Safety of PEP on Skin Graft Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steven L. Moran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rion LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of a biological agent called PEP in&#xD;
      people who have a skin graft donor site wound.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label phase 1 study of PEP (a leukocyte depleted blood preparation derived&#xD;
      from human U.S. sourced pooled apheresed platelets) in patients with at least two donor&#xD;
      split-thickness skin graft wounds. One donor site will be treated with the standard&#xD;
      post-operative dressing, while the other site will be treated with PEP or PEP+TISSEEL and&#xD;
      covered with a standard dressing. TISSEEL is a commercially available fibrin sealant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 2 weeks (within the first 14 days) for each dosing cohort</time_frame>
    <description>Number of participants who experience DLTs of grade 3 or higher adverse reaction identified within the first 2 weeks of study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of PEP</measure>
    <time_frame>Up to 2 weeks (within the first 14 days) for each dosing cohort</time_frame>
    <description>Determined by testing increasing doses of PEP from 10% to 20% on dose escalation cohorts 1 to 2. The first cohort of three patients will be treated at the starting dose of 10% PEP and observed for at least two weeks from start of treatment to assess toxicity. If dose-limiting toxicity (DLT) is not seen in any of the first 3 patients, up to 3 new patients will be accrued and treated at the next higher dose level of 20% PEP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of treatment-related adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Skin Graft</condition>
  <arm_group>
    <arm_group_label>10 % PEP only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Subjects will receive 10% PEP to the skin graft donor wound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20% PEP only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Subjects will receive 20% PEP to the skin graft donor wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10% PEP and TISSEEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: Subjects will receive 10% PEP and TISSEEL to the skin graft donor wound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20% PEP and TISSEEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4: Subjects will receive 20% PEP and TISSEEL to the skin graft donor wound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10% PEP</intervention_name>
    <description>PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.</description>
    <arm_group_label>10 % PEP only</arm_group_label>
    <arm_group_label>10% PEP and TISSEEL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TISSEEL</intervention_name>
    <description>Fibrin sealant made from pooled human plasma</description>
    <arm_group_label>10% PEP and TISSEEL</arm_group_label>
    <arm_group_label>20% PEP and TISSEEL</arm_group_label>
    <other_name>fibrin sealant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>20% PEP</intervention_name>
    <description>PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.</description>
    <arm_group_label>20% PEP and TISSEEL</arm_group_label>
    <arm_group_label>20% PEP only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females 18 years of age or older.&#xD;
&#xD;
          -  Requiring at least two 40 cm^2 or larger split-thickness skin grafts by a Mayo Clinic&#xD;
             plastic surgeon or dermatologist.&#xD;
&#xD;
          -  Skin graft that meets all of the following criteria:&#xD;
&#xD;
          -  Each graft site has a size of 40 cm^2 ;&#xD;
&#xD;
          -  Located anywhere on the body (with exception of oral mucosal membranes);&#xD;
&#xD;
          -  Split-thickness skin graft wound depth of between 8/1000-14/1000 inch.&#xD;
&#xD;
          -  Ability to safely undergo skin graft harvest procedure.&#xD;
&#xD;
          -  Capacity to provide informed consent&#xD;
&#xD;
          -  Ability to comply with protocol.&#xD;
&#xD;
          -  Subject is judged, by the clinical investigator, to be healthy as evidenced by lack of&#xD;
             clinically significant abnormal findings on medical history, physical examination,&#xD;
             vital signs, and clinical laboratory tests.&#xD;
&#xD;
          -  Patient is able and willing to return to study site for all follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Actively undergoing cancer treatment.&#xD;
&#xD;
          -  Known history of MRSA (methicillin-resistant staphylococcus aureus).&#xD;
&#xD;
          -  Known hypersensitivity to aprotinin (Trasylol®).&#xD;
&#xD;
          -  Subjects who are positive for hepatitis B surface antigen (HbsAg), hepatitis C&#xD;
             antibody or HIV.&#xD;
&#xD;
          -  Any known allergy or sensitivity to adhesive dressings (e.g., Tegaderm).&#xD;
&#xD;
          -  Clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic,&#xD;
             neurological, psychiatric, immunological, gastrointestinal, hematological, or&#xD;
             metabolic disease that is, in the opinion of the investigator, not stabilized or may&#xD;
             otherwise impact the results of the study.&#xD;
&#xD;
          -  Patients on systemic immunosuppression, or have systemic autoimmune or chronic&#xD;
             inflammatory disease.&#xD;
&#xD;
          -  Subjects with hepatic impairment.&#xD;
&#xD;
          -  Participation in another clinical study in the past 30 days or concurrent&#xD;
             participation in another clinical trial.&#xD;
&#xD;
          -  Patients with poorly controlled diabetes mellitus (HbA1C ≥ 8%).&#xD;
&#xD;
          -  Patients with known peripheral neuropathy, or known concomitant vascular problems&#xD;
             (such as peripheral artery disease, arterial insufficiency, or venous hypertension) or&#xD;
             calciphylaxis.&#xD;
&#xD;
          -  Currently on or planned to receive hyperbaric wound therapy.&#xD;
&#xD;
          -  Pregnant or lactating female patients.&#xD;
&#xD;
          -  Sexually active woman of child bearing potential who is unwilling to use approved&#xD;
             contraception method for three months after receiving dose of investigational drug&#xD;
&#xD;
          -  Prisoners.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Moran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Steven L. Moran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>ALL IPD that underlie the results in a publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Prior to study initiation, the study protocol and informed consent form will be provided to Rion, LLC. During the study, all safety reports (as they happen or quarterly), and all SAEs as they happen will be reported to Rion, LLC. At the end of the study after database is locked, a formal clinical study report will be provided to Rion, LLC.</ipd_time_frame>
    <ipd_access_criteria>IPD will only be shared with the collaborator Rion LLC</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

